JMP Securities Maintains Market Outperform on Larimar Therapeutics, Raises Price Target to $16
JMP Securities analyst Jonathan Wolleben maintains Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and raises the price target from $10 to $16.
Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
After One Year Of Regulatory Hold, Larimar’s Ataxia Candidate Sees Some Hope
The FDA has cleared the initiation of Larimar Therapeutics Inc’s (NASDAQ:LRMR) 25 mg cohort of Phase 2 trial of CTI-1601 in Friedreich’s…
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session
Gainers
Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.
S&P 500, Nasdaq Futures Point Higher As Investors Await Key Consumer Sentiment Data
U.S. index futures are pointing to a moderately positive open on Wall Street on Friday following the lackluster close in the previous session.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…